Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Trial status:Recruiting
Trial ID:
BNT327-06
NCT ID:
NCT06712316
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting

Trial Details

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

Medical Condition
  • Lung Cancer
    • Trial Drug
  • BNT327
    • See more
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Paclitaxel
    • Phase
    Phase 2/Phase 3
    Type
    Interventional
    Estimated Enrolment
    982
    Estimated Trial Date
    Jan 2025 - Dec 2029

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    Alaska Oncology and Hematology, LLC
    Anchorage, Alaska, United States, 99508
    Status
    Recruiting
    Location
    Clermont Oncology Center
    Clermont, Florida, United States, 34711
    Status
    Recruiting
    Location
    Millennium Research and Clinical Development, LLC
    Houston, Texas, United States, 77090
    Status
    Recruiting
    Location
    Peninsula & South Eastern Haematology and Oncology Group
    Frankston, Australia, 3199
    Status
    Recruiting